

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: IMAGIN MEDICAL INC. (the "Issuer").

Trading Symbol: IME

Number of Outstanding Listed Securities: 39,772,634

Date: July 31, 2016

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business** See attached news release dated July 20, 2016

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact. On July 20, 2016, the Company reported that the process of retrofitting and requalifying components to optimize the design of the i/Blue Imaging System was on schedule. As previously announced, the i/Blue Alpha Prototype A was successfully moved from Lawrence Livermore National Lab to the University of Rochester Laboratory for Laser Energetics where Dr. Stavros Demos, the inventor of the technology, continues to assist the Imagin team with the development of the Alpha Prototype B.

2. Provide a general overview and discussion of the activities of management.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship..
8. Describe the acquisition of new customers or loss of customers.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
11. Report on any labour disputes and resolutions of those disputes if applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common shares	Nil		

---

**FORM 7 – MONTHLY PROGRESS REPORT**

--	--	--	--

(1) *State aggregate proceeds and intended allocation of proceeds.* **\$nil**

15. Provide details of any loans to or by Related Persons.
16. Provide details of any changes in directors, officers or committee members.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated August 7, 2016.

**WILLIAM GALINE**

Name of Director or Senior Officer



Signature

**Director & Corp.Sec.**

Official Capacity

<b>Issuer Details</b> Name of Issuer <b>IMAGIN MEDICAL INC.</b>	For Month End <b>July 2016</b>	Date of Report YY/MM/D <b>August 7, 2016</b>
Issuer Address <b>600 – 890 Pender St.</b>		
City/Province/Postal Code <b>Vancouver, B.C. V6C 1J9</b>	Issuer Fax No.	Issuer Telephone No. <b>775-737-3292</b>
Contact Name <b>WILLIAM GALINE</b>	Contact Position <b>Director</b>	Contact Telephone No. <b>775-737-3292</b>
Contact Email Address <b>billgaline@gmail.com</b>	Web Site Address <a href="http://imaginmedical.com">http://imaginmedical.com</a>	

CSE Symbol: IME  
OTC PINK Symbol: IMEXF  
Frankfurt/Stuttgart Stock Exchanges: DPD2

NR-2016-IME-13

## ALPHA PROTOTYPE REQUALIFICATION ON SCHEDULE

*Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in the early detection of bladder cancer through endoscopes.*

---

Vancouver, B.C. and Boston, MA, July 20, 2016 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that the process of retrofitting and requalifying components to optimize the design of the i/Blue Imaging System is on schedule. As previously announced, the i/Blue Alpha Prototype A was successfully moved from Lawrence Livermore National Lab to the University of Rochester Laboratory for Laser Energetics where Dr. Stavros Demos, the inventor of the technology, continues to assist the Imagin team with the development of the Alpha Prototype B.

Three key components that will differentiate this instrument in the market place are being requalified, including fiber optic cables, specialty cameras and the required processing software, all of which have been defined and in process to be integrated into the Alpha Prototype B. The new cable connecting the cystoscope to the i/Blue systems will contain over 335,000 fibers, more than double the fiber count of the original prototype. The camera being used is the highest light sensitive scientific model available. The software required to integrate all the components is being developed by Dr. Ronald Wood, whose services have been added to the contract with of the University of Rochester Medical Center. Dr. Wood has solid experience in this area and has conducted previous bladder studies. The Company believes the project is on schedule for year-end 2016.

“We have developed a positive relationship with the University of Rochester Medical Center and the Laboratory for Laser Energetics and we’re excited to work with them to facilitate Imagin’s success,” said Mike Vergano, Imagin’s Director of Engineering and Operations.

### ***About Imagin Medical***

*Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect*

cancer. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at [www.imaginmedical.com](http://www.imaginmedical.com).

**ON BEHALF OF THE BOARD:**

*Jim Hutchens,*

President & CEO

**For further information, contact:**

Bill Galine, Investor Relations

Telephone: (775) 737-3292

Email: [billgaline@gmail.com](mailto:billgaline@gmail.com)

**CAUTIONARY DISCLAIMER STATEMENT:** *The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.*

*This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the Canadian Securities Exchange and other risks detailed from time to time in the filings made by the Company with securities regulations.*

*The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.*